Cytochrome P450 3A and 2B6 in the developing kidney: Implications for ifosfamide nephrotoxicity

Pediatric Nephrology

Volumn 20, Issue 7, 2005, Pages 872-885

  Aleksa, Katarina ^a,b   Matsell, Doug ^d   Krausz, Kris ^c   Gelboin, Harry ^c   Ito, Shinya ^a,b   Koren, Gideon ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

^d BC CHILDREN S HOSPITAL   (Canada)

Author keywords

CYP2B6; CYP3A; Enantioselective metabolism; Ifosfamide; Kidney; Nephrotoxicity; Ontogeny

Indexed keywords

CHLOROACETALDEHYDE; CYTOCHROME P450 2B6; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; IFOSFAMIDE;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; CHILD; CONTROLLED STUDY; DRUG METABOLISM; DRUG RESPONSE; ENANTIOMER; ENZYME ACTIVITY; ENZYME INHIBITION; FETUS; GENETIC VARIABILITY; GESTATION PERIOD; HUMAN; HUMAN TISSUE; INFANT; KIDNEY DEVELOPMENT; KIDNEY METABOLISM; KIDNEY MICROSOME; LIVER METABOLISM; NEPHROTOXICITY; ONTOGENY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 CYP3A; FETUS; HUMANS; IFOSFAMIDE; IMMUNOHISTOCHEMISTRY; INFANT; KIDNEY; MICROSOMES; MIDDLE AGED; OXIDOREDUCTASES, N-DEMETHYLATING; STEREOISOMERISM;

EID: 21344450763     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-004-1807-3     Document Type: Article

References (68)

1. Pryde PG, Sedman AB, Nugent CE, Barr M Jr (1993) Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol 9:1575-1582
2. Aleksa K, Ito S, Koren G (2001) Developmental renal tubular toxicity; a hypothetical frame work and experimental approaches. Curr Therap Res Clin Exper 71:930-941 10.1016/S0011-393X(01)80096-5
3. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH (2003) Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14:1-10 10.1097/01.ASN.0000042803.28024.92
4. Lohr JW, Willsky GR, Acara MA (1998) Renal drug metabolism. Pharmacol Rev 50:107-141 1:CAS:528:DyaK1cXitlylsrY%3D
5. Hosseinpour F, Norlin M, Wikvall K (2002) Kidney microsomal 25- and 1alpha-hydroxylase in vitamin D metabolism: Catalytic properties, molecular cloning, cellular localization and expression during development. Biochim Biophys Acta 1580:133-144 1:CAS:528:DC%2BD38Xjt1Khu74%3D
6. Schuetz EG, Schuetz JD, Grogan WM, Naray-Fejes-Toth A, Fejes-Toth G, Raucy J, Guzelian P, Gionela K, Watlington CO (1992) Expression of cytochrome P450 3A in amphibian, rat and human kidney. Arch Biochem Biophys 206-214
7. Poon K, PangKS (1995) Benzoic acid glycine conjugation in the isolated perfused rat kidney. Drug Metab Dispos 23:255-260 1:CAS:528:DyaK2MXjslWqt7g%3D
8. Grauer FG (2001) Prevention of hospital-acquired acute renal failure. WALTHAM Focus 11 4-10
9. BC Cancer Agency (2003) Ifosfamide monograph. www.bccancer.bc.ca
10. Cancer Care Ontario (2003) Ifosfamide. Cancer Care Ontario
11. Munoz M, Bonjoch J, Prat J, Pujol M, Girona V, Bolos J (2003) Degradation kinetics of ifosfamide in aqueous solution. Int J Pharm 139:249-253
12. Mulders TM, Keizer Ouwerkerk J, van der Velde EA, Breimer DD, Mulder GJ (1995) Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers. Clin Cancer Res 1:1525-1536 1:CAS:528:DyaK28XmvVWiuw%3D%3D
13. Kaijser GP, Beijnen JH, Bult A, Hogeboom MH, Underberg WJ (1991) A systematic study on the chemical stability of ifosfamide. J Pharm Biomed Anal 9:1061-1067 10.1016/0731-7085(91)80045-B
14. Burton LC, James CA (1988) Rapid method for the determination of ifosfamide and cyclophosphamide in plasma by high-performance liquid chromatography with solid-phase extraction. J Chromatogr 431:450-454 1:CAS:528:DyaL1cXmt1WkurY%3D
15. Springate J, Zamlauski-Tucker MJ, Lu H, Chan KK (1997) Renal clearance of ifosfamide. Drug Metab Dispos 25:1081-1082 1:CAS:528:DyaK2sXmt1Wqtr0%3D
16. Morland BJ, Mann JR, Milford DV, Raafat F, Stevens MC (1996) Ifosfamide nephrotoxicity in children: Histopathological features in two cases. Med Pediatr Oncol 27:57-61 10.1002/ (SICI)1096-911X(199607)27:1<57::AID-MPO11>3.0.CO;2-2
17. Granvil CP, Madan A, Sharkawi M, Parkinson A, Wainer IW (1999) Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metab Dispos 4:533-541
18. Roy P, Tretyakov O, Wright J, Waxman DJ (1999) Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug Metab Dispos 11:1309-1318
19. Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson AD, Beaune PH (1994) Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 3:1157-1163 10.1016/0006-2952(94)90387-5
20. Aleksa K, Ito S, Koren G (2004) Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: Pharmacokinetic modeling for estimation of intracellular levels. J Lab Clin Med 144:159-162 10.1016/ j.lab.2003.10.013
21. Loebstein R, Atanakovic G, Bishai R, Wolpin J, Khattak S, Hashemi G, Gobrail M, Baruchel S, Ito S, Koren G (1999) Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 39:454-461 1:CAS:528:DC%2BD3cXivFWqtQ%3D%3D
22. Gelboin HV, Krausz KW, Goldfarb I, Buters JT, Yang SK, Gonzalez FJ, Korzekwa KR, Shou M (1995) Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. Biochem Pharmacol 50:1841-1850 10.1016/0006-2952(95)02077-2
23. Yang TJ, Krausz KW, Shou M, Yang SK, Buters JT, Gonzalez FJ, Gelboin HV (1998) Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol 55:1633-1640 10.1016/S0006-2952(98)00018-5
24. Doucet JP, Trifaro JM (1988) A discontinuous and highly porous sodium dodecyl sulfate-polyacrylamide slab gel system of high resolution. Anal Biochem 168:265-271 10.1016/0003-2697(88)90317-X
25. Spatzenegger M, Liu H, Wang Q, Debarber A, Koop DR, Halpert JR (2003) Analysis of differential substrate selectivities of CYP2B6 and CYP2E1 by site-directed mutagenesis and molecular modeling. J Pharmacol Exp Ther 304:477-487 10.1124/jpet.102.043323
26. Domanski TL, Schultz KM, Roussel F, Stevens JC, Halpert JR (1999) Structure-function analysis of human cytochrome P-450 2B6 using a novel substrate, site-directed mutagenesis, and molecular modeling. J Pharmacol Exp Ther 290:1141-1147 1:CAS:528:DyaK1MXlsVOqsbo%3D
27. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TKH, Waxman DJ (1997) Human cytochrome P4502B6-interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 25:985-993 1:CAS:528:DyaK2sXlsVGmsrc%3D
28. Rae JM, Soukhova NV, Flockhart DA, Desta Z (2002) Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: Implications for cyclophosphamide metabolism. Drug Metab Dispos 5:525-530 10.1124/dmd.30.5.525
29. Kerbusch T, de Kraker J, Mathjt RA, Beijne JH (2001) Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: A sparse sampling approach. Clin Pharmacokinet 48:615-625
30. Wainer IW, Ducharme J, Granvil CP (1996) The N-dechloroethylation of ifosfamide: Using stereochemistry to obtain an accurate picture of a clinically relevant metabolic pathway. Cancer Chemother Pharmacol 332-336
31. Chang TKH, Weber GF, Crespi CL, Waxman DJ (1993) Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Research 53:5629-5637 1:CAS:528:DyaK2cXpsV2mtA%3D%3D
32. Gilard V, Martino R, Malet-Martino M, Niemeyer U, Pohl J (1999) Chemical stability and fate of the cytostatic drug ifosfamide and its N-dechloroethylated metabolites in acidic aqueous solutions. J Med Chem 42:2542-2560 10.1021/jm980587g
33. Springate JE (1997) Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. J Appl Toxicol 1:75-79 10.1002/ (SICI)1099-1263(199701)17:1<75::AID-JAT397>3.3.CO;2-3
34. Jakobsson SW, Okita RT, Mock NI, Masters BS, Buja LM, Prough RA (1982). Monooxygenase activities of human liver, lung, and kidney microsomes-a study of 42 post mortem cases. Acta Pharmacol Toxicol (Copenh) 50:332-341
35. Okita RT, Jakobsson SW, Prough RA, Masters BS (1979) Lauric acid hydroxylation in human liver and kidney cortex microsomes. Biochem Pharmacol 23:3385-3390 10.1016/0006-2952(79)90077-7
36. Mohandas J, Duggin GG, Horvath JS, Tiller DJ (1981) Metabolic oxidation of acetaminophen (paracetamol) mediated by cytochrome P-450 mixed-function oxidase and prostaglandin endoperoxide synthetase in rabbit kidney. Toxicol Appl Pharmacol 61:252-259 10.1016/ 0041-008X(81)90415-4
37. Mohandas J, Duggin GG, Horvath JS, Tiller DJ (1981) Regional differences in peroxidatic activation of paracetamol (acetaminophen) mediated by cytochrome P450 and prostaglandin endoperoxide synthetase in rabbit kidney. Res Commun Chem Pathol Pharmacol 34:69-80 1:CAS:528:DyaL38XksFyjuw%3D%3D
38. Hart SG, Cartun RW, Wyand DS, Khairallah EA, Cohen SD (1995) Immunohistochemical localization of acetaminophen in target tissues of the CD-1 mouse: Correspondence of covalent binding with toxicity. Fundam Appl Toxicol 2:260-274 10.1006/faat.1995.1029
39. Kuo CH, Rush GF, Hook JB (1982) Renal cortical accumulation of phenobarbital in rats and rabbits: Lack of correlation with induction of renal microsomal monooxygenases. J Pharmacol Exp Ther 220:547-551 1:CAS:528:DyaL38XhvFarur8%3D
40. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, et al (1999) Human CYP2B6: Expression, inducibility and catalytic activities. Pharmacogenetics 9:295-306 1:CAS:528:DyaK1MXlsFGlsrk%3D
41. Ohishi N, Imaoka S, Funae Y (1994) Changes in content of P450 isozymes in hepatic and renal microsomes of the male rat treated with cis-diamminedichloroplatinum. Xenobiotica 9:873-880
42. Jollie DR, Maines MD (1985) Effect of cis-platinum on kidney cytochrome P-450 and heme metabolism: Evidence for the regulatory role of the pituitary hormones. Arch Biochem Biophys 240:51-59 10.1016/ 0003-9861(85)90007-4
43. Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB, Hall SD (1996) Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 50:52-59 1:CAS:528:DyaK28XksVylsrs%3D
44. Huang Z, Roy P, Waxman DJ (2000) Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem Pharmacol 59:961-972 10.1016/S0006-2952(99)00410-4
45. Granvil CP, Ducharme J, Leyland-Jones B, Trudeau M, Wainer IW (1996) Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients. Cancer Chemother Pharmacol 27:451-456 10.1007/s002800050411
46. Alcorn J, McNamara PJ (2002) Ontogeny of hepatic and renal systemic clearance pathways in infants: Part I. Clin Pharmacokinet 41:959-998 1:CAS:528:DC%2BD38XotlGisbk%3D
47. Bissinger RL (1995) Renal physiology, part 1: Structure and function. Neonatal Netw 14:9-20 1:STN:280:ByqA3czgvFQ%3D
48. Yang HY, Lee QP, Rettie AE, Juchau MR (1994) Functional cytochrome P4503A isoforms in human embryonic tissues: Expression during organogenesis. Mol Pharmacol 46:922-928 1:CAS:528:DyaK2MXitlOlsrg%3D
49. Hakkola J, Tanaka E, Pelkonen O (1998) Developmental expression of cytochrome P450 enzymes in human liver. Pharmacol Toxicol 82:209-217 1:CAS:528:DyaK1cXjsVynuro%3D
50. Leggat JE, Johnson KJ, Kolars JC, Schmiedlin-Ren P, Watkins PB, Leightman AB (1994) Immunohistochemical localization of cytochrome P450 3A in normal and neoplastic kidney and urinary bladder epithelium. J Am Soc Nephrol 786
51. Murray GI, Barnes TS, Sewell HF, Ewen SW, Melvin WT, Burke MD (1988) The immunocytochemical localisation and distribution of cytochrome P-450 in normal human hepatic and extrahepatic tissues with a monoclonal antibody to human cytochrome P-450. Br J Clin Pharmacol 25:465-475 1:CAS:528:DyaL1cXkt1Slsr0%3D
52. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M (2003) Comparative analysis of cyp3a expression in human liver suggests only a minor role for cyp3a5 in drug metabolism. Drug Metab Dispos 31:755-761 10.1124/dmd.31.6.755
53. Stevens JC, Hines RN, Gu C, Koukouritaki SB, Manro JR, Tandler PJ, Zaya MJ (2003) Developmental Expression of the Major Human Hepatic CYP3A Enzymes. J Pharmacol Exp Ther 307:573-582 10.1124/jpet.103.054841
54. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T (1997) Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 247:625-634 10.1111/ j.1432-1033.1997.00625.x
55. Michalets EL (1998) Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18:84-112 1:CAS:528:DyaK1cXpt1ylug%3D%3D
56. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, Wojnowski L (2002) Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30:1108-1114 10.1124/dmd.30.10.1108
57. Xie HG, Kim RB, Wood AJ, Stein CM (2001) Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 41:815-850 10.1146/annurev.pharmtox.41.1.815
58. Liu J, Callahan SM, Brunner LJ (2003) Effect of sodium alterations on hepatic cytochrome P450 3A2 and 2C11 and renal function in rats. Drug Dev Ind Pharm 7:767-775 10.1081/DDC-120021776
59. Wang MH, Smith A, Zhou Y, Chang HH, Lin S, Zhao X, Imig JD, Dorrance AM (2003) Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. Hypertension 41:594-599 10.1161/ 01.HYP.0000090123.55365.BA
60. Warren GW, Poloyac SM, Gary DS, Mattson MP, Blouin RA (1999) Hepatic cytochrome P-450 expression in tumor necrosis factor-alpha receptor (p55/ p75) knockout mice after endotoxin administration. J Pharmacol Exp Ther 288:945-950 1:CAS:528:DyaK1MXhs1KjtbY%3D
61. Stresser DM, Kupfer D (1999) Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metab Dispos 27:517-525 1:CAS:528:DyaK1MXislShtLw%3D
62. Kerbusch T, de Kraker J, Keizer HJ, van Putten JW, Groen HJ, Jansen RL, Schellens JH, Beijnen JH (2001) Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 40:41-62 1:CAS:528:DC%2BD3MXhslKhtrk%3D
63. Kerbusch T, Mathot RA, Keizer HJ, Kaijser GP, Schellens JH, Beijnen JH (2001) Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. Drug Metab Dispos 29:967-975 1:CAS:528:DC%2BD3MXksFCntr0%3D
64. Boddy, A. V., Cole, M., Pearson, A. D. and Idle, J. R. (1995). The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 53-60.
65. Wagner T (1994) Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet 26:439-456 1:CAS:528:DyaK2cXlvFCksLw%3D
66. Kurowski V, Wagner T (1993) Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 33:36-42 10.1007/ BF00686020
67. Lewis LD, Fitzgerald DL, Harper PG, Rogers HJ (1990) Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 30:725-732 1:STN:280:By6C3cvivFY%3D
68. Aleksa K, Halachmi N, Ito S, Koren G (2004) Renal ontogeny of ifosfamide nephrotoxicity. J Lab Clin Med 144 (6):285-293 10.1016/j.lab.2004.09.002